Rising costs, unpredictable policies, and dwindling incentives are forcing Big Pharma to rethink the UK, with leading firms pausing multi-million-pound R&D projects, but why is the country losing its competitive edge?
Cannabis (hemp) contains up to 150 different terpenes. They not only determine the smell, but they also have valuable properties for the body as studies show. Katharina Zedlacher, from BioBloom GmbH, discusses the effect of terpenes in CBD full extracts.
Dr Vincent Maida discusses his discoveries and pioneering research in the area of using Topical Cannabis-Based Medicines (TCBM) for integumentary and wound management.
Peter Jackson, Executive Director of the AMR Centre, describes new initiatives and partnerships that point the way forward for the UK’s antimicrobial resistance response.
Prof Colin J Suckling OBE DSc FRSE from the Department of Pure & Applied Chemistry, details the ‘why’ and ‘what’ of academic drug discovery research at the University of Strathclyde, as well as his thoughts on the value of a chemistry degree.
With attention turning in the U.S. and elsewhere to how cannabis businesses are banked, John Binns, Partner at BCL Solicitors LLP, gets into the weeds of how UK banks have been addressing the issue, as well as the prospects for improvement.
